Preliminary research indicates that a small panel of biomarkers targeting various biological pathways (e.g. inflammation, vascular, renal) may be useful in helping to predict adverse outcomes in patients with chronic heart failure. Information from a seven biomarker panel provided higher predictive accuracy than the currently validated Seattle Heart Failure Model. The researchers now hope to extend the utility of the model beyond its initial scope to include groups at risk for other types of heart failure.
